COMMUNIQUÉS West-GlobeNewswire

Physeon Bolsters Management Team with New Appointments
17/12/2018
Experienced Executives Join Physeon Team on Heels of Commencement of US VIVA Trial SCHAFFHAUSEN, Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical [...]
The Governance Institute Announces Governance Technology Partnership with Nasdaq
17/12/2018
Provides membership access to Nasdaq’s next generation and award-winning board portal and collaboration software, Nasdaq Boardvantage® LINCOLN, Neb. and NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- The Governance [...]
Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019
17/12/2018
Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro RALEIGH, N.C., Dec. 17, [...]
PotNetwork Holdings Inc. Prepares for Surge in Interstate Commerce Following 2018 US Hemp Farm Bill
17/12/2018
Industry-leading Subsidiary Diamond CBD Inc., Poised to Capture Evolving Consumer Market, Prepares for Revolutionary Industry Changes FORT LAUDERDALE, Fla., Dec. 17, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- [...]
Spectral Announces Results of a Face-to-Face meeting with the U.S. FDA
17/12/2018
TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT) , a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]
CLS Holdings USA Positioned for Growth in 2019
17/12/2018
LAS VEGAS, Dec. 17, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]
Cancer Genetics Terminates Proposed Merger with NovellusDx
17/12/2018
RUTHERFORD, N.J., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17/12/2018
AC5™ provides a new option for the treatment of topical wounds FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and [...]
Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection
17/12/2018
Press release Malmö, Sweden December 17, 2018 Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection Acarix has initiated a new explorative clinical study to develop a [...]
Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2019.
17/12/2018
Latvia, 2018-12-17 13:34 CET (GLOBE NEWSWIRE) -- Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2019: Consolidated not audited interim report for the 12 months of 2018 - 18.02. [...]
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
17/12/2018
U.S. Phase 2 Study to Begin in First Quarter of 2019 NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell [...]
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
17/12/2018
TORONTO and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics [...]
TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology
17/12/2018
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) and Dana-Farber Cancer Institute today announced the publication of results from the multicenter Phase 1/1b trial of umbralisib (TGR-1202 [...]
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17/12/2018
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. [...]
Dova Pharmaceuticals Announces Management Changes
17/12/2018
Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of $2.4 to $2.7 million for [...]
Loop Industries Appoints Sidney Horn to Board of Directors
17/12/2018
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (Nasdaq:Loop) (“Loop” or the “Company”), a leading technology innovator in sustainable plastic, announced today that its ‎Board of Directors has [...]
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
17/12/2018
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]
Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis
17/12/2018
BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company and the U.S. Food and Drug [...]
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
17/12/2018
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects Top-line data anticipated [...]

Pages